Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.39 USD | -1.16% | +6.54% | +16.62% |
Mar. 06 | Aerovate Therapeutics, Inc. Announces Board Changes | CI |
Dec. 08 | Aerovate Therapeutics Insider Sold Shares Worth $165,628, According to a Recent SEC Filing | MT |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 730M |
---|---|---|---|---|---|
Net income 2023 * | -73M | Net income 2024 * | -83M | EV / Sales 2023 * | - |
Net cash position 2023 * | 121M | Net cash position 2024 * | 63.08M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-9.29
x | P/E ratio 2024 * |
-10.3
x | Employees | 43 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 99.97% |
1 day | -1.16% | ||
1 week | +6.54% | ||
Current month | +14.34% | ||
1 month | +26.21% | ||
3 months | +55.24% | ||
6 months | +96.21% | ||
Current year | +16.62% |
Managers | Title | Age | Since |
---|---|---|---|
Benjamin Dake
FOU | Founder | 48 | 18-07-26 |
Timothy P. Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
George Eldridge
DFI | Director of Finance/CFO | 61 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Santel
BRD | Director/Board Member | 62 | 23-01-18 |
Maha Katabi
BRD | Director/Board Member | 50 | 20-07-31 |
Timothy P. Noyes
CEO | Chief Executive Officer | 62 | 21-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.00% | 8 M€ | +6.48% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 26.39 | -1.16% | 191,434 |
24-03-15 | 26.7 | +9.92% | 105,613 |
24-03-14 | 24.29 | -9.97% | 75,160 |
24-03-13 | 26.98 | +11.76% | 104,171 |
24-03-12 | 24.14 | -2.54% | 302,231 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.62% | 730M | |
+9.72% | 46.21B | |
+34.27% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |